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ABSTRACT
Objectives: Urothelial carcinoma and prostatic adenocarcinoma are the most common tumors of genitourinary system. Both tumors can demonstrate 
a broad morphology or present as poorly differentiated carcinoma occurring in urinary bladder or prostate or both organs that raise the suspicion of 
a locally extending or metastatic carcinoma from either organs. Accurate distinction between these tumors is mandatory because of different tumor 
biology and therapeutic protocols. In equivocal tumor morphology, the primary option is to use immunohistochemical panel in surgical pathology that 
includes differentiation markers that will assist pathologists to avoid misdiagnosis. The aim of this study is immunohistochemical evaluation of GATA3 
in urothelial carcinoma and prostatic adenocarcinoma with correlation to different clinicopathological parameters.
Methods: We used formalin-fixed paraffin-embedded tissue blocks from 51 patients of urothelial carcinoma and 15 patients of prostatic 
adenocarcinoma including different grades, stages, and types. Monoclonal antibody for GATA3 was used for immunohistochemical staining of tissue 
sections, and GATA3 expression was semi-quantitatively scored using H-score method.
Results: Of 51 urothelial carcinomas, 96% were GATA3 positive with a mean H-score = 212. No correlation between GATA3 expression and 
clinicopathological parameters includes grade and stage. Lower GATA3 expression was noted in urothelial carcinoma variants. All of prostatic 
adenocarcinoma cases did not show GATA3 reactivity.
Conclusion: GATA3 reactivity is a reliable factor to confirm diagnosis of urothelial carcinoma and exclude prostatic adenocarcinoma. The routine use 
of GATA3 as differentiation marker for urothelial carcinoma may be advocated based on the results of this study.
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INTRODUCTION
Bladder cancer is the 9th most common cancer worldwide. More than 
90% are urothelial carcinoma. Urothelial carcinoma is 3–4 times more 
common in males than females [1]. And its more common after 60 years 
of age [1]. Tobacco smoking, chemical exposure, and schistosomiasis 
are major risk factors [2-5].
Urothelial carcinomas morphology ranges from papillary to flat, 
noninvasive to invasive, and low grade to high grade. It is believed that 
the accumulation of successive genetic alterations rather than a single 
genetic event determines a tumor’s phenotype and, subsequently, the 
patient’s clinical outcome.
Papillary urothelial carcinoma is divided into low-grade and high-grade 
categories [6]. It represents 70–80% of newly diagnosed bladder cancer 
patients and presents with noninvasive or early invasive disease (stages 
Tis, Ta, or T1). The prognosis of these patients depends on tumor grade. 
Whereas all infiltrating carcinomas are considered as high grade, their 
outcomes depend on the stage of the tumor rather than the grade [7]. 
The outcome of invasive tumors depends on the stage.
Prostate carcinoma is the second most common cancer in the world 
[1]. Its incidence increases dramatically with age; more than 75% of 
patients are 65 years or older ages. Environmental and genetic factors 
have important roles. Well-documented familial association with 
5–10 times increased risk in men with multiple affected 1st degree 
relatives [8]. High androgen levels may cause and accelerate the 
prostate cancer development [9]. Majority of prostatic adenocarcinoma 
cases are asymptomatic diagnosed during PSA screening [10].
Most prostatic adenocarcinomas are composed of acini arranged in one 
or more patterns. The diagnosis relies on a combination of architectural 
and cytological findings. The grade is one of the strongest predictors of 
biologic behavior in prostate cancer. The Gleason score is recommended 
for routine use in grading [11].
GATA3 is a transcription factor, encoded by GATA3 gene located on 
chromosome 10p14 in humans [12] that regulates development and 
function of various normal tissues and may be expressed in these tissues 
and in their neoplasms. GATA3 was first identified as an important 
regulator of T-cell development [13,14]. In bladder, GATA3 expression 
in bladder cancer lower than normal urothelium, this suggested that 
decrease GATA3 expression may be necessary for tumor initiation or 
maintenance [15].
METHODS
This retrospective study was carried out in Babylon training center for 
Pathology, Faculty of Medicine, Babylon University, during the period 
from December 2017 to 2018.
Ethical clearance for this study was obtained from the Scientific 
Committee, College of Medicine, Babylon University.
The study group composed of formalin-fixed paraffin-embedded 
tissue blocks from 66 cases that were collected from laboratory of 
histopathology in Al-Hilla Teaching Hospital in Babylon and from some 
private laboratories in this governorate. 51 cases of urothelial carcinoma 
of the urinary bladder including 40 males and 11 females with a mean 
age of 70.2 years, and 15 cases of prostatic adenocarcinoma with a 
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mean age of 72.3 years were included in this study. Biopsy type for 
urothelial carcinoma cases was TURBT, whereas most of the prostatic 
adenocarcinoma were true-cut biopsy (n=8), TURP (n=4), and open 
prostatectomy (n=3).
From each tissue block, two sections were stained with hematoxylin/
eosin (H and E) staining method and immunohistochemical polydetector 
plus horseradish peroxidase staining method using monoclonal mouse 
antihuman GATA3 protein, ready-to-use, Bio SB. Clone L50-823, USA.
The criterion for positive immunohistochemical reaction is dark 
brown precipitate in the nucleus for GATA3. The score was assessed by 
calculation of H-score for each slide according to the following equation 
[16]: H-score = [1 × (% cells 1+) + 2 × (% cells 2+) + 3 × (% cells 3+)]
Where, 3+ = strong, 2+= moderate, and 1+= weak staining intensity.
Statistical analysis was performed using SPSS version software 24. 
p<0.05 was considered statistically significant.
RESULTS
A total of 51 cases of urothelial carcinoma and 15 cases of prostatic 
adenocarcinoma were studied, distributed as shown in Table 1.
Immunohistochemical positive results for GATA3 were determined as 
nuclear staining of malignant cells, and accordingly, we categorized the 
results using H-score which is semi-quantitative assessment involves 
intensity of nuclear staining and percentage of tumor cells stained.
Accordingly, H-score ranged from 0 to 300. As in previous studies [16], 
in this study, the results were recorded as positive when H-score was 
more than 10. GATA3 sensitivity in urothelial carcinomas at that score 
Table 1: Distribution of urothelial carcinoma and prostatic 
adenocarcinoma cases according to different clinicopathological 





























Prostatic adenocarcinoma 40–59 2 (13.3)
60–79 9 (60)





Fig. 1: Infiltrating high grade urothelial carcinoma with high 
H-score for GATA 3 (X400)
Fig. 2: Low grade Papillary urothelial carcinoma, with high H- 
score for GATA 3 ( X200)
was 96%. All positive staining results were non-focal and most cases 
73% (37/49) show diffuse moderate to strong staining (Figs. 1 and 2).
No significant correlation of GATA3 immunostaining with grade and 
stage of tumor (p>0.05). Extremely significant correlation of GATA3 
immunostaining with type of tumor (p<0.01) as shown in Table 2.
While all of the 15 prostatic adenocarcinoma cases showed completely 
negative staining, the specificity of GATA3 in urothelial carcinoma 
was 100%. Our results also revealed a highly significant difference 
in GATA3 immunoexpression for urothelial carcinoma & prostatic 
adenocarcinoma (p<0.01).
DISCUSSION
Most of the prostatic adenocarcinoma and urothelial carcinoma cases can 
be distinguished using the routine H and E method, but there are some 
challenging cases in which the distinction between the two is not possible.
In poorly differentiated carcinoma affecting prostate and bladder 
without clear-cut morphologic features to ascertain a specific 
diagnosis, immunohistochemical evaluation is mandatory because it 
may represent a local extension of tumor from one organ to the other or 
a case of two primary tumors.
There are several immunohistochemical markers for prostatic 
adenocarcinoma including PSA, AMACR, P501, and NKX3.1 can be used 
with high sensitivity and specificity. However, in rare cases, all markers 
are negative so prostatic origin cannot be excluded from the study.
For urothelial carcinoma, there is no single immunohistochemical 
marker with constant and high sensitivity and specificity; therefore, 
urothelial origin could be proved using a panel of markers such as 
HMWK, p63, S100P, thrombomodulin, and uroplakin.
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This study presents a review of 66 primary tumors including 
51 cases of urothelial carcinoma classified according to the WHO 
classification 2016 [16] and 15 cases of prostatic adenocarcinoma 
graded according to Gleason grade group system 2015 [10], with the 
aim to investigate the frequencies of various clinicopathological and 
histopathological features and their correlations to GATA3 protein 
expression.
In the current study, we used a semi-quantitative method to evaluate 
expression level of GATA3 called H-score that incorporated the intensity 
of nuclear immune reactivity and the proportion of positively stained 
cell nuclei. We found that mean H-score was 212 (range 30–285).
In reviewing previous studies, most analyzed GATA3 expression using 
different scoring methods. Oh et al. [17] depended on more than 10% of 
cells stained to be positive regardless intensity. Liu et al. [18] considered 
<5% of cells stained to be a negative result. Recently, two studies used 
H-score method for GATA3 evaluation in urothelial carcinoma. Clark 
et al. [19] have shown that mean H-score for GATA3 expression in 
urothelial carcinoma was 170 depending on more than 10 as cutoff 
value for positive results. Leivo et al. [20] have found that the median 
H-score was 240 (range 10–300) without specifying the cutoff value in 
the article. In our work, we used a low H-score (>10) as cutoff value.
Reports of GATA3 sensitivity in urothelial carcinoma extend from 67% 
to 99%. In the current study, GATA3 had high sensitivity in urothelial 
carcinoma among all published studies, where it was 96% (49/51) 
that was close to Clark et al. [19] study 95% (21/22), Miettinen 
et al. [23] study 90% (49/54), and Leivo et al. [20] study 99% (88/89), 
who used the same source of primary antibody (Bio SB, Clone L50-
823) of our study. This differs from GATA3 sensitivity in two larger 
studies, Higgins et al. [21] found 67% of 308 cases and Oh et al. [17] 
found 84.8% of 138 cases. The difference may be excused due to 
larger study groups, different primary antibody source, and inherent 
nature of tissue blocks.
Diffuse strong staining reaction (H-score >150) was noticed in 73% of 
urothelial carcinoma cases. Liu et al. [18] found 65% of 72 cases and 
Chang et al. [22] found 89% of 35 cases revealed strong diffuse staining. 
This variation in degrees of expression may be resulted from varied 
scoring methods and different case selection methods, where all cases 
used in both studies were high-grade muscle invasive.
In keeping with Leivo et al. [20] study, along with our study, has 
demonstrated that no significant association between GATA3 expression 
and urothelial carcinoma grade (p=0.07) and stage (p=0.378). On the 
other hand, Higgins et al. [21] reported that higher GATA3 expression 
in low grade (95%) compared with high-grade (57%) urothelial 
carcinoma. The larger study group used by Higgins may be the cause 
of different rates.
Significant association was reported between GATA3 expression and 
microscopic type (p<0.01) in our study. All conventional urothelial 
carcinomas (papillary and infiltrating) were GATA3 positive, while 
four urothelial carcinomas with divergent differentiation showed low 
to negative GATA3 immunoreactivity, but the number of variant cases 
included in our study was too small to draw any definitive conclusion 
in this regard.
Similar observations were found by Miettinen et al. [23] who reported 
5/54 GATA3 negative cases including urothelial carcinomas with 
squamous differentiation. In the same context, Rao et al. [24] study 
stated that GATA3 expressed in 2/11 (18%) of urothelial carcinomas 
with glandular differentiation.
In contrast to our results, Helmy et al. [25] found that 70% of 10 
urothelial carcinoma with squamous differentiation cases were GATA3 
positive (p=0.01). The variability in reported results could be attributed 
to different methodology used including case selection and source of 
primary antibody.
There were several studies assessing the expression of GATA3 in 
urothelial carcinoma in comparison to prostatic adenocarcinoma. 
Highly significant correlation was found (p<0.01) in the present study, 
where all studied prostatic adenocarcinoma cases were not express any 
GATA3 reactivity. In all of the above-mentioned studies [19,20,23,26], 
none of studied prostatic adenocarcinoma cases showed GATA3 
positivity, except in Miettinen et al. study [23] who reported 2% (2/95) 
of prostatic adenocarcinoma cases with positive reaction.
CONCLUSION
The high sensitivity of GATA3 makes it the first-line immunohistochemical 
marker for diagnosing urothelial carcinoma, whether as primary tumor 
in the bladder or metastatic carcinoma from urinary bladder in other 
sites, along with clinical and morphologic findings. GATA3 seems to be 
less sensitive in detecting variant urothelial carcinomas in comparison 
with conventional urothelial carcinoma.
AUTHORS’ CONTRIBUTION
Weam Hamzah Abdullah has majorly performed the experiment in 
the laboratory, collecting tissues samples, data analysis, and editing 
the article with references. Hadeel Abdulelah Kerbel has provided the 
design, intellectual content, innovations, and protocol for conducting 
the experiment along with membership. Rafid Fakhir Al Husseini has a 
minor role in conducting the experiment in the laboratory, analysis of 
obtained data, and sincerely authored article.
CONFLICTS OF INTEREST
The authors declare that there are no conflicts of interest regarding the 
publication in this article.
Table 2: Correlation of GATA3 reactivity with urothelial carcinoma grades, stages, and microscopic types
Clinicopathological parameters n (%) p value
Positive Negative Total 
Grade
Low 31 (100) 0 (0) 31 (60.8) 0.07
High 18 (90) 2 (10) 20 (39.2)
Stage
Ta 3 (100) 0 (0) 3 (5.8) 0.378
T1 26 (100) 0 (0) 26 (50.9)
T2 16 (89) 2 (11) 18 (35.3)
T3 2 (100) 0 (0) 2 (3.9)
T4 2 (100) 0 (0) 2 (3.9)
Microscopic type
Papillary 41 (100) 0 (0) 41 (80.3) 0.01
Conventional infiltrating 6 (100) 0 (0) 6 (11.7)
Infiltrating with divergent differentiation 2 (50) 2 (50) 4 (7.8)
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